市場調査レポート

間葉系幹細胞の世界市場

Mesenchymal Stem Cells

発行 Global Industry Analysts, Inc. 商品コード 297189
出版日 ページ情報 英文 179 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
間葉系幹細胞の世界市場 Mesenchymal Stem Cells
出版日: 2014年01月01日 ページ情報: 英文 179 Pages
概要

当レポートでは、間葉系幹細胞の世界市場について分析しております。また米国、カナダ、日本、欧州、アジア太平洋地域およびその他の地域の各地域についてそれぞれ包括的分析を提供すると共に、2009年から2018年までの各年ごとの見積りと予測をお伝え致します。さらに主要企業とニッチ企業を含む51社のプロファイルを交えつつ、概略下記内容でお届け致します。

第1章 序、調査方法および製品の定義

  • 調査の信頼性と報告の制約
  • 免責事項
  • データの解釈と報告レベル
  • 製品の定義と調査の範囲

第2章 エグゼクティブサマリー

  • 市場の概観
    • 間葉系幹細胞 - 医学における次の大きな飛躍
    • 現在および将来の分析
    • 間葉系幹細胞療法の現状と将来
    • 間葉系幹細胞治療:主なパイプライン製品のリスト(2013年12月現在)
    • 「既製」間葉系幹細胞の普及事業化が現実味を帯びる
    • ソフトウェア企業はこのブームで儲けようとしている
  • 市場促進要因、動向および課題
    • 人口の高齢化が間葉系幹細胞療法の需要を牽引
    • 胚性幹細胞研究についての議論が止まないのに対し、成体幹細胞療法は成長軌道に乗っている
    • 成体幹細胞および胚性幹細胞 - 比較
    • 間葉系幹細胞 対 胚または人工多能性幹細胞
    • 間葉系幹細胞療法は胚性幹細胞に適用される倫理問題の影響を受けない
    • 間葉系幹細胞 - 「標的化ドラッグデリバリー」に使える可能性のある運搬手段
    • 生体内特性に関連した抜け穴が療法の進歩を促す
    • 間葉系幹細胞市場に立ちはだかる大きな課題
  • 幹細胞市場 - マクロ的視点
    • 間葉系幹細胞が支配的
    • 幹細胞研究が急速に進んでいる
    • これまでの主な成果
    • 幹細胞研究分野における主な歴史的な出来事
    • 幹細胞研究を規制する法律 - 規制の概要
    • 主な国々における幹細胞研究に対する法規制
    • 市場のダイナミクスおよび動向
    • 北米が世界の幹細胞研究を支配
    • 幹細胞療法はコンセプトから現実に移り続ける
    • 幹細胞は医学における非常に大きな可能性の前兆となる
    • 長らく待たれている幹細胞療法に対する要請
    • 韓国が世界初の体性幹細胞ベースの治療を実施
    • 幹細胞市場に対する主な制約
    • 幹細胞ツーリズム- ブームか破滅のもとか?
    • 奇形腫 - もはや幹細胞治療の開発に対する障害ではない
    • 米国と日本が幹細胞特許で欧州に先行
    • 幹細胞治療の開発を抑制する課題
  • 主な幹細胞の変形の概況
    • 成体幹細胞
    • 低リスクの投資
    • 成体幹細胞は研究用投資をさらに集める
    • 多様性の低さ - 成体幹細胞の主な制約要因
    • 造血幹細胞 - 不朽の成功を収める
    • 制約要因
    • 人工多能性幹細胞 - ESCの代替
    • iPSの発見
    • 医薬品開発 - IPSの主なアプリケーション
    • 再生医療のためのiPSの使用
    • iPS細胞バンクの確立
    • 難治性および先天性疾患治療
    • 医学を変貌させる胚性幹細胞
    • 倫理問題や技術的なハードルがhESC研究を足踏みさせる
    • 安全性と有効性のデータの不足 - 主な懸念
  • アプリケーション別の間葉系幹細胞研究
    • 整形外科における間葉系幹細胞
    • 整形手術のための間葉系幹細胞ベースのモデル
    • 療法を必要とする領域への間葉系幹細胞の配布
    • 変形性関節症治療における間葉系幹細胞
    • 関節リウマチ治療における間葉系幹細胞
    • がん治療における間葉系幹細胞
    • 肝臓学における間葉系幹細胞
    • 神経学における間葉系幹細胞
    • 放射線治療における間葉系幹細胞
    • 糖尿病治療における間葉系幹細胞
    • 自己免疫疾患治療における間葉系幹細胞
    • 早発卵巣不全の治療における間葉系幹細胞
    • 遺伝子治療における間葉系幹細胞
    • 肺疾患治療における間葉系幹細胞
    • 結腸修復における間葉系幹細胞
    • 腎修復における間葉系幹細胞
  • 製品の概要
    • 間葉系幹細胞(MSC)- はじめに
    • 歴史
    • 同種間葉系幹細胞とは何か?
    • なぜ間葉系幹細胞はそんなに人気があるのか?
    • 間葉系幹細胞のいくつかの主な供給源
    • 骨髄
    • ウォートンのゼリーおよび臍帯血
    • 脂肪組織
    • 栄養膜組織
    • 羊水
    • 下顎智歯の歯芽を開発
    • 間葉系幹細胞治療のメカニズム
    • 間葉系幹細胞の重要な機能
    • 形態学
    • 識別/検出
    • 分化能
    • 免疫調節作用
    • 培養
    • 臨床用途
    • 臨床グレード間葉系幹細胞の生産
    • 間葉系幹細胞の欠点
  • 製品の革新と発売
    • Vitro Biopharma は一連の新しい幹細胞産製品を発表
    • Rainbow Scientific は Biological Industriesの幹細胞培養システムを発売
    • LABSは生物製剤スクリーニング用の新しいラボテストを発表
    • Vitro Diagnostics は一連の新製品を発表
    • IntelliCell BioSciences は非生物脂肪組織から間質血管画分細胞を開発
    • Vitro Diagnostics は細胞治療のための新製品を発表
    • Vitro Diagnostics は複数の幹細胞製品を発表
  • 最近の業界動向
    • Life TechnologiesはHarvard Universityとライセンスおよび幹細胞共同研究契約を締結
    • Stemedica Cell Technologies と Life Technologies は世界的な販売契約を締結
    • ThermoGenesis はThermoLineの資産をHelmer Scientificに売却
    • Athersysは虚血性脳卒中におけるMultiStem細胞療法の第2相臨床試験の拡大のためのMHRAの承認を受ける
    • Osiris Therapeutics はEMAからのProchymal®に対しオーファンドラッグ指定を受ける
    • 他31例
  • 主な企業
    • Aastrom Biosciences, Inc. (米国)
    • Cell Applications, Inc (米国)
    • Celprogen, Inc (米国)
    • Cyagen Biosciences Inc (米国)
    • EMD Millipore Corporation (米国)
    • 他15社
  • 世界市場展望

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
  • アジア太平洋地域
  • その他の地域
目次
Product Code: MCP-7815

This report analyzes the worldwide markets for Mesenchymal Stem Cells (MSCs) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 51 companies including many key and niche players such as -

Aastrom Biosciences, Inc.
Cell Applications, Inc.
Celprogen, Inc.
Cyagen Biosciences Inc.
EMD Millipore Corporation
Genlantis, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Mesenchymal Stem Cells - The Next Big Leap in Medicine
  • Current and Future Analysis
  • The Present and Future of MSC Therapies
    • Table 1: Percentage Share Breakdown of Mesenchymal Stem Cells (MSCs) Clinical Trials by Region (2013) (includes corresponding Graph/Chart)
  • Mesenchymal Stem cell Therapies: A List of Select Pipeline Products (as of December 2013)
  • Widespread Commercialization of 'Off-the-Shelf' MSCs to Become a Reality
  • Software Companies Endeavour to Cash in on the Boom

2. MARKET DRIVERS, TRENDS & ISSUES

  • Ageing Demographics to Drive Demand for Mesenchymal Stem Cell Therapies
    • Table 2: Global Population Statistics for the 65+ Age Group (2013E) (includes corresponding Graph/Chart)
  • Adult Stem Cells Therapies on Growth Trajectory, as Controversies Continue to Haunt Embryonic Stem Cell Research
  • Adult Stem Cells and Embryonic Stem Cells - A Comparison
  • MSCs versus Embryonic or Induced Pluripotent Stem Cells
  • MSC Therapies Immune to Ethical Issues Applicable to Embryonic Stem Cells
  • MSCs - A Potential Vehicle for 'Targeted Drug Delivery'
  • Loopholes Associated with In Vivo Properties Constrain Therapeutic Advancements
  • Major Challenges Confronting Mesenchymal Stem Cell Market

3. STEM CELL MARKET - A MACRO PERSPECTIVE

  • Mesenchymal Stem Cells Dominate
  • Stem Cell Research in Top Gear
    • Table 3: Global Stem Cell Usage in Research (2013): Percentage Share Breakdown by Type (includes corresponding Graph/Chart)
    • Table 4: Percentage Share Breakdown of Stem Cell Clinical Trials by Country (2012) (includes corresponding Graph/Chart)
  • Major Achievements Thus Far
  • A Glimpse of Major Historical Events in the Area of Stem Cell Research
  • Laws Governing Stem Cells Research - A Regulatory Overview
  • Laws and Regulations in Stem Cells Research in Select Countries
  • Market Dynamics and Trends
  • North America Dominates Global Stem Cells Research
    • Table 5: World 10-Year Perspective for Adult Stem Cell Research by Geographic Region - Percentage Breakdown of Annual Investments for US, Europe and Rest of World Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)
  • Stem Cell Therapy Continues to Traverse from Concept to Reality
  • Stem Cells Bode Tremendous Potential in Medicine
  • Long Wait Imperative for Stem Cell Therapies
  • Korea Debuts the World's First Somatic Stem Cell Based Therapy
  • Key Restraints for Stem Cell Market
    • Ethical Issues
    • Insurance Coverage
  • Stem Cell Tourism - A Boon or Bane?
    • Government Regulations Fail to Prevent Rise in Stem Cell Tourism
  • Teratomas - No Longer an Impediment to Stem Cell Therapy Development
  • US and Japan Surge Ahead of Europe in Stem Cell Patents
    • Table 6: Global Stem Cells Patent Analysis by Market (2010): Percentage Breakdown of Number of Patents Issued for US, Japan and Europe (includes corresponding Graph/Chart)
    • Table 7: Global Stem Cells Patent Analysis by Product (2010): Percentage Breakdown of Number of Patents Issued for Adult Stem Cells, Human Embryonic Stem Cells, Mesenchymal Stem Cells, Hematopoietic Stem Cells, Neuronal Stem Cells and Others (includes corresponding Graph/Chart)
    • Table 8: Leading Stem Cell Companies by Patents (2010): Percentage Breakdown of Number of Patents Secured for Geron Corp., Osiris Therapeutics, Olympus Corporation, Wisconsin Alumni Research Foundation, Kourion Therapeutics AG, Japan Science & Tech Agency and Others (includes corresponding Graph/Chart)
  • Issues Hold Back Development of Stem Cell Therapies
    • Advantages and Drawbacks of Various Stem Cells

4. REVIEW OF SELECT MAJOR STEM CELL VARIANTS

  • Adult Stem Cells
  • A Low Risk Investment
  • Adult Stem Cells Garner More Investments for Research
  • Low Versatility - A Major Limiting Factor of Adult Stem Cells
  • Hematopoietic Stem Cells - Enjoying Enduring Success
  • Restraining Factors
  • Induced Pluripotent Stem Cells - An Alternative to ESCs
  • A Peek into the Discovery of iPS
  • Drug Development - A Major Application for iPS
  • Use of iPS for Regenerative Medicine
  • Establishing iPS Cell Banks
  • Intractable and Congenital Disease Treatments
  • Embryonic Stem Cells to Transfigure Medicine
  • Ethical Issues and Technical Hurdles Bog Down hESC Research
  • Lack of Safety and Efficacy Data - A Key Concern

5. MESENCHYMAL STEM CELL RESEARCH BY APPLICATION

  • Mesenchymal Stem Cells in Orthopedics
  • MSC based Models for Orthopedic Repair
  • Delivery of MSCs to Regions Requiring Therapy
  • MSCs in the Treatment of Osteoarthritis
  • MSCs in the Treatment of Rheumatoid Arthritis
  • MSCs in Cancer Treatment
  • MSCs in Hepatology
  • MSCs in Neurology
  • MSCs in Cardiology
  • MSCs in Radiotherapy
  • MSCs in the Treatment of Diabetes
  • MSCs in the Treatment of Autoimmune Diseases
  • MSCs in Treatment of Premature Ovarian Failure
  • MSCs for Gene Therapy
  • MSC Therapy in the Treatment of Lung Diseases
  • MSCs in Colon Repair
  • MSCs in Kidney Repair

6. PRODUCT OVERVIEW

  • Mesenchymal Stem Cells (MSCs) - An Introduction
  • History
  • What Are Allogeneic Mesenchymal Stem Cells?
  • Why Are MSCs So Popular?
  • Some Major Sources of Mesenchymal Stem Cells
  • Bone Marrow
  • Wharton's Jelly and Umbilical Cord Blood
  • Adipose Tissue
  • Trophoblastic Tissues
  • Amniotic Fluid
  • Developing Tooth Bud of Mandibular Third Molar
  • Mechanism of Mesenchymal Stem Cell Therapy
  • Important Features of Mesenchymal Stem Cells
  • Morphology
  • Identification/Detection
  • Differentiation Capacity
  • Immuno-modulatory Effects
  • Culturing
  • Clinical Use
  • Production of Clinical-Grade MSCs
  • Drawbacks of MSCs

7. PRODUCT INNOVATIONS/LAUNCHES

  • Vitro Biopharma Unveils New Range of Stem Cell Products
  • Rainbow Scientific Launches Biological Industries' Stem Cell Culture Systems
  • LABS Unveils New Laboratory Test for Screening Biologic Products
  • Vitro Diagnostics Launches New Range of Products
  • IntelliCell BioSciences Develops Stromal Vascular Fraction Cells from Non-living Adipose Tissues
  • Vitro Diagnostics Unveils New Products for Cell Therapy
  • Vitro Diagnostics Launches Multiple Stem Cell Products

8. RECENT INDUSTRY ACTIVITY

  • Life Technologies Inks License and Collaborative Stem Cell Research Agreement with Harvard University
  • Stemedica Cell Technologies and Life Technologies Ink Global Distribution Agreement
  • Stemedica Asia and Kalbe's Stem Cell and Cancer Institute Ink Definitive Licensing Agreement
  • ThermoGenesis Divests ThermoLine Assets to Helmer Scientific
  • ThermoGenesis Inks Definitive Merger Agreement with TotiRx
  • ThermoGenesis Obtains Registration Approval or AXP® AutoXpress® in China
  • Athersys Receives MHRA Approval for the Expansion of Phase 2 Clinical Trial of MultiStem Cell Therapy in Ischemic Stroke
  • Osiris Therapeutics Receives Orphan Drug Designation for Prochymal® from EMA
  • Stemedica Commences Phase II Stroke Trial for Stemedyne-MSC
  • RNL Bio Undergoes Name Change to K-STECMCELL
  • Mesoblast Secures US FDA Approval to Manufacture MSCs in Singapore
  • Fibrocell Science and UCLA Ink Exclusive Agreement
  • Stemedica Enters into an Agreement with Scripps Research Institute
  • GE Healthcare Inks Licensing Agreement with Cellular Dynamics International
  • GE Healthcare and BGI Ink Multi-year Research Collaboration Agreement
  • Osiris Therapeutics Reacquires Rights to Chondrogen and Prochymal from Genzyme
  • Vitro BioPharma Enters into Distribution Agreement with StemGenesis
  • ThermoGenesis and Golden Meditech Ink Product Purchase and Distribution Agreement
  • Vitro Biopharma Announces Expansion of Partnership with Neuromics
  • Cryo-Save Enters into Collaboration with Policlinico "Gemelli" University Hospital
  • Cryosite Enters into Collaboration with Regeneus
  • Fibrocell and UCLA Discover Rare Adult Stem Cell Subtypes
  • Mesoblast Receives Approval for Phase II Type 2 Diabetes Study
  • Athersys Receives US Patent for MultiStem in the Treatment of GvHD
  • Stemedica Receives FDA Approval for Phase II Clinical Trial of Ischemia Tolerant MSCs
  • Fast Forward and Athersys Sign Sponsored Research Agreement
  • ScreenCell® Inks Global Collaboration and Distribution Agreement with Transgenomic
  • Mesoblast Enters into Partnership with Lonza Group
  • China Sky One Medical to Inaugurate Harbin Tian Xin Biological Engineering
  • MedRebels Succeeds in Reducing Inflammation in Knee Joints by Injecting Bone Marrow Stem Cells
  • RenovoCyte Inks Partnership Agreement with VetCell
  • Mesoblast Performs First Minimally Invasive Procedure for Lumbar Disc Repair in Phase II Clinical Trials of MPC Product
  • AlloSource Inks Licensing Agreement with NuVasive
  • Cephalon Inks Strategic Alliance with Mesoblast
  • Aastrom and ATEK Medical Ink Manufacturing and Development Partnership
  • Osiris Therapeutics Obtains FDA Orphan Drug Designation for Stem Cell Product for Type 1 Diabetes

9. FOCUS ON SELECT PLAYERS

  • Aastrom Biosciences, Inc. (US)
  • Cell Applications, Inc (US)
  • Celprogen, Inc (US)
  • Cyagen Biosciences Inc (US)
  • EMD Millipore Corporation (US)
  • Genlantis, Inc. (US)
  • Life Technologies Corporation (US)
  • Lonza Group (Switzerland)
  • Mesoblast Limited (Australia)
  • Neuromics (US)
  • Osiris Therapeutics, Inc. (US)
  • Orthofix International N.V. (Curacao)
  • PromoCell GmbH (Germany)
  • R&D Systems, Inc (US)
  • ScienCell Research Laboratories (US)
  • Stemcell Technologies Inc (Canada)
  • Stemedica Cell Technologies, Inc. (US)
  • StemGenesis (US)
  • Trevigen, Inc. (US)
  • Vitro Biopharma (US)

10. GLOBAL MARKET PERSPECTIVE

    • Table 9: Global Recent Past, Current & Future Analysis for Mesenchymal Stem Cells by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 Through 2018 (includes corresponding Graph/Chart)
    • Table 10: World 10-Year Perspective for Mesenchymal Stem Cells by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2009, 2013 & 2018 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current and Future Analysis
    • Rapidly Ageing Population: A Major Driving Demand for MSC based Therapies
    • Table 11: North American Elderly Population by Age Group (1975-2050) (includes corresponding Graph/Chart)
    • Overview of the US Stem Cells Market
    • Rising Governmental Investments in Stem Cell Therapies - A Growth Booster
    • FDA Issues Warning Against Illegal Stem Cell Therapies
    • US Regulates Stem Cells as Drugs
    • Federal Law on Stem Cells in the US
    • NIH at the Forefront of Research Funding
      • NIH Guidelines on Stem Cell Research Funding
    • Bans and Restrictions on Stem Cell Research
    • American Type Culture Collection Inc (ATCC) - A Major Non-Profit Organization
    • Product Launches
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 12: US Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current and Future Analysis
    • Stem Cell Regulations
    • Stemcell Technologies Inc - A Key Player
  • B. Market Analytics
    • Table 13: Canadian Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current and Future Analysis
    • New Regulation for Accelerated Stem Cell Approval and Its Impact on Stem Cells Product Market
  • B. Market Analytics
    • Table 14: Japanese Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Ageing Population to Drive Demand for MSC based Therapies
    • Table 15: Population Breakup by Age Group for Select European Countries: 2012 (as a Percentage of Total Population) (includes corresponding Graph/Chart)
    • Legislations on Stem Cell Research and Therapy in the EU
    • Unproven Stem Cell Therapies Receive Government Backing in the EU?
    • Scientists and Government Tussle over Safety of Stamina Foundation's MSC Therapy in Italy
    • Stem Cell Clinics Shut Down in Germany due to Malpractices
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 16: European Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Current and Future Analysis
    • Overview of Select Countries
      • Australia
      • Stem Cell Tourism - A Popular Trend in Australia
      • South Korea
      • South Korea Pacing towards Regaining Lost Glory in Stem Cell Research
      • South Korea Upbeat on Stem Cell Therapy Market Potential
      • India
      • An Outline of the Stem Cell Research Structure in India
    • Table 17: Indian Adult Stem Cell Research (2012): Percentage Share Breakdown by Type (includes corresponding Graph/Chart)
      • A Regulatory Picture of the Indian Stem Cell Research and Therapy
      • Adult Stem Cells - A Highly Money-Spinning Market
      • Indians 'Bank' on Dental Stem Cells
      • New Zealand
      • Stem Cell Research Scenario in New Zealand
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 18: Asia-Pacific Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Current and Future Analysis
    • Stem Cell Research in Full Swing in Israel
    • Key Players
  • B. Market Analytics
    • Table 19: Rest of World Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top